TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06607458: Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatmen

Sponsor: Delcath Systems Inc. · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 90 pts

Competing Trials Overlap

13 Active Trials

Excess Burn Exposure

$3,280,200

Rescue Site Savings

+$2,171,400

Unlock Full NCT06607458 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06607458 Rescue Dossier →